Medicine
Xiidra 50 mg/mL eye drops
Xiidra 50 mg/mL eye drops is a prescription medicine containing Lifitegrast for ophthalmic use, marketed by Bausch & Lomb, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F). Store single-use containers in the…
Key facts
- Active ingredient (INN)
- Lifitegrast
- Brand
- Xiidra
- Strength
- 50 mg/mL
- Dosage form
- Eye drops
- Route
- Ophthalmic
- Packs
- 12 pouches
- Marketing authorisation holder
- Bausch & Lomb
- Manufacturers
- Bausch & LombNovartis Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F). Store single-use containers in the original foil pouch.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- S01XA25 Lifitegrast
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 11 July 2016
- Identifiers
- RxCUI 1801835, 1801840DailyMed set ID 1a914080-a3c0-44be-b601-0ae3160e77eb, 8589d376-ac10-4ddb-9c53-2e0c8d5675c4NDC 24208-911, 0078-0911Application NDA208073
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 12 pouch in 1 carton / 5 ampule in 1 pouch / .2 mL in 1 ampule | 24208-911-12 | Bausch & Lomb | 2 January 2024 |
| 12 pouch in 1 carton / 5 ampule in 1 pouch / .2 mL in 1 ampule | 0078-0911-12 | Novartis Pharmaceuticals | 4 June 2020 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Lifitegrast
Clinical summary
Lifitegrast is a lymphocyte function-associated antigen-1 antagonist indicated for the treatment of the signs and symptoms of dry eye disease (DED). It is available as eye drops and powder for ophthalmic solution. MedsAcross supplies Lifitegrast for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about LifitegrastFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Xiidra prescribing information (Novartis Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Xiidra 50 mg/mL eye drops for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.